欢迎访问《现代生物医学进展》编辑部！

目的：分析影响干扰素-α（IFN-α）治疗慢性乙型肝炎(CHB)疗效的因素。方法：选择2006 年到2009 年青岛市传染病医院住院的CHB 患者46 例，应用IFN-α 治疗48 周，根据IFN-α 治疗的疗效将其分为应答组与无应答组，评价患者的宿主、病毒载量及生化指标等因素对疗效的影响。结果：两组间的性别比例、年龄和病程无显著差异（P＞0.05），应答组治疗前HBV-DNA 载量低于无应答组，ALT 水平高于无应答组，HBeAg 阳性患者的应答率高于HBeAg 阴性患者，差异均具有统计学意义（P＜0.05），应答组在治疗12 周时HBV-DNA 载量下降＞2log 的比例高于无应答组，差异具有统计学意义（P＜0.05）。结论：治疗前HBV DNA 载量低、ALT 水平高和HBeAg 阳性以及治疗12 周时的HBV DNA 应答可以作为干扰素-α 治疗慢性乙型肝炎48 周时应答的预测因素。

英文摘要:

Objective: To investigate the influencing factors of the efficacy of interferon α (IFN-α) on patients with chronic hepatitis B (CHB). Methods: 46 cases of CHB patients were chosen in this study, who were treated with IFN-α for 48 weeks in Qingdao Hospital for Infectious Diseases from January 2006 to June 2009, which were divided into responding group and non-responding group according to the efficacy of IFN-α. The influence of host factors, viral loads and biochemical factors on the efficacy of IFN-α was detected. Results: The proportions of sex and the mean ages and courses of disease were similar in the two groups (P> 0.05). The pre-treatment HBV-DNA loads were lower and the ALT levels were higher in responding group than those in non-responding group (P <0.05), while the responding rate of the patients with HBeAg positive was higher than that with HBeAg negative (P <0.05). The rate of HBV-DNA load decreased more than that of 2 log at the 12 weeks of treatment was significantly higher in the responding group than that in the non-responding group (P <0.05). Conclusion: The lower HBV DNA load, higher ALT level and HBeAg positive before treatment and the response of HBV DNA at the week 12 of treatment may be the predicting factors of the response at week 48 of IFN-α treatment in the CHB patients.

View Full Text View/Add Comment Download reader